Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-068039
Filing Date
2025-05-09
Accepted
2025-05-09 16:15:03
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 13515
  Complete submission text file 0000950170-25-068039.txt   15223
Mailing Address 29 NEWBURY STREET, 3RD FLOOR BOSTON MA 02116
Business Address 29 NEWBURY STREET, 3RD FLOOR BOSTON MA 02116 617-585-2000
Third Rock Ventures IV, L.P. (Filed by) CIK: 0001688327 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Subject) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94841 | Film No.: 25930596
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)